Viking Therapeutics
Develops clinical-stage therapies for obesity, metabolic and endocrine disorders.
Something off on this page? Send us feedback.
Profile
Drug candidates target obesity, metabolic and endocrine disorders. The pipeline spans injectable and oral VK2735, plus VK2809, VK0214, VK5211 and DACRA programs.
Clinical development focuses on metabolic and endocrine therapies, led by injectable and oral VK2735 for obesity. Other named programs include VK2809 for lipid and metabolic disorders, VK0214 for X-linked adrenoleukodystrophy, VK5211, and DACRA candidates for obesity and metabolic disease.
Viking is a clinical-stage biopharmaceutical company based in San Diego, with subsidiaries in Australia and Ireland and worldwide rights to several Ligand assets. Its pipeline combines licensed technology with internally developed programs.
Clinical trials and regulatory interactions shape program advancement. Viking has a manufacturing and supply agreement for VK2735 and is building commercial capabilities. Several program assets remain materially dependent on Ligand licenses.
Company facts
Key statistics
Year to date −9.3% · Average volume (30d) 1.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| May 28, 2026 | Lake Street | Target | $89 | ||
| May 27, 2026 | Truist Financial | Target | $75 | $83 | |
| Apr 30, 2026 | Morgan Stanley | Target | $99 | $95 | |
| Apr 30, 2026 | Cantor Fitzgerald | Reiterate | Overweight | $105 | $100 |
| Mar 12, 2026 | Jefferies | Target | $110 | $101 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | −$1.23 | −$1.10 | +10.6% | — | — | — | −0.96% |
| Apr 29, 2026Q1 FY26 | −$1.01 | −$1.37 | −35.6% | — | — | — | −0.48% |
| Feb 11, 2026Q4 FY25 | −$0.89 | −$1.38 | −55.1% | $1.9M | — | — | +6.80% |
| Oct 22, 2025Q3 FY25 | −$0.70 | −$0.81 | −15.7% | — | — | — | +7.96% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | −$114.0K | −$94.0K | $0 | $0 | |
| Operating income | −$55.5M | −$74.6M | −$98.6M | −$164.7M | −$164.1M | −$132.6M | |
| Net income | −$45.6M | −$65.6M | −$90.8M | −$157.7M | −$158.3M | −$128.0M | |
| Diluted EPS | −$0.41 | −$0.58 | −$0.81 | −$1.38 | −$1.37 | −$1.10 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $501.7M · Total debt $4.1M · Total assets $521.9M · Shareholders' equity $408.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 116.65M · Float 113.39M · 97.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 6.34M | 5.43% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 6.19M | 5.31% | 13F | Aug 7, 2026 |
| State Street Corp | 5.61M | 4.81% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.05M | 4.33% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 4.48M | 3.84% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 29, 2026 | Marianna Mancini | officer: Chief Operating Officer | −18,217 | $33.47 |
| Jul 29, 2026 | Greg Zante | officer: Chief Financial Officer | −21,217 | $33.47 |
| Jul 29, 2026 | Brian Lian | director, officer: President & CEO | −148,517 | $33.32 |
| Mar 10, 2026 | Neil William Aubuchon | officer: Chief Commercial Officer | +4,475 | $33.50 |
| Jan 2, 2026 | Matthew W. Foehr | director | −16,000 | $35.11 |
Peers
- Eli Lilly
Marketed dual agonist plus oral GLP-1 obesity medicines
- Novo Nordisk (ADR)
Marketed semaglutide and next-generation obesity platform
- Madrigal Pharmaceuticals
Approved liver-directed THR-beta therapy for MASH
- Amgen
Phase 3 antibody-peptide obesity medicine with infrequent dosing
- Altimmune
GLP-1/glucagon dual agonist in Phase 3-planned MASH
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Viking Therapeutics | $32.24 | +0.31% | $3.75B | — | — | — | — |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Madrigal Pharmaceuticals | $533.76 | −0.02% | $12.33B | — | — | 9.6 | +71.2% |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Altimmune | $3.12 | −0.12% | $604.8M | — | — | 19,510.1 | +820.0% |
| Median | 26.9 | 18.4 | 9.6 | +47.7% |